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Abstract
Background: To examine whether whole genome expression profiling could reveal changes in mRNA expression
of peripheral blood mononuclear cells (PBMC) from allergic patients undergoing rush immunotherapy (RIT) that
might be manifest within the first few months of treatment.
Methods: For this study, PBMC from three allergic patients undergoing RIT were assessed at four timepoints: prior
to RIT, at 1 week and 7 week post-RIT, during build-up and at 4 months, after establishment of a maintenance
dose. PBMC mRNA gene expression changes over time were determined by oligonucleotide microarrays using the
Illumina Human-6 BeadChip Platform, which simultaneously interrogates expression profiles of > 47,000 transcripts.
Differentially expressed genes were identified using well-established statistical analysis for microarrays. In addition,
we analyzed peripheral blood basophil high-affinity IgE receptor (Fc epsilon RI) expression and T-regulatory cell
frequency as detected by expression of CD3
+CD4
+CD25bright cells at each timepoint using flow cytometry.
Results: In comparing the initial 2 timepoints with the final 2 timepoints and analyzing for genes with ≥1.5-fold
expression change (p less than or equal to 0.05, BH-FDR), we identified 507 transcripts. At a 2-fold change (p less
than or equal to 0.05, BH-FDR), we found 44 transcripts. Of these, 28 were up-regulated and 16 were down-
regulated genes. From these datasets, we have identified changes in immunologically relevant genes from both
the innate and adaptive response with upregulation of expressed genes for molecules including IL-1b, IL-8, CD40L,
BTK and BCL6. At the 4 month timepoint, we noted a downward trend in Fc epsilon RI expression in each of the
three patients and increased allergen-specific IgG4 levels. No change was seen in the frequency of peripheral T-
regulatory cells expressed over the four timepoints.
Conclusions: We observed significant changes in gene expression early in peripheral blood samples from allergic
patients undergoing RIT. Moreover, serum levels for allergen specific IgG4 also increased over the course of
treatment. These studies suggest that RIT induces rapid and dynamic alterations in both innate and adaptive
immunity which can be observed in the periphery of allergic patients. These alterations could be directly related to
the therapeutic shift in the allergen-specific class of immunoglobulin.
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Introduction
While a number of immunologic changes occur with
allergen immunotherapy (IT), the relationship of these
various changes to the overall effectiveness of IT is
unclear. There are several immunologic changes seen
with IT, including: decreases in allergen-specific IgE,
increases in IgG4 “blocking” antibodies, suppression of
the classic TH2 cytokines with a rise in TH1 cytokine
expression, and an increase in the frequency of T-regula-
tory cell populations [1-3].
Rush IT (RIT) is a form of accelerated IT where patients
undergo a series of dose escalating injections over a single
or two-day period in order to achieve a maintenance dose
earlier than with conventional IT. This form of IT has
been proven to be both safe and effective [4,5].
Genome-wide transcriptional profiling has been shown
to be a useful tool to identify and classify human diseases.
Gene expression profiling has been used to identify
* Correspondence: laurie.davis@utsouthwestern.edu
1Department of Internal Medicine, Division of Rheumatic Diseases, University
of Texas Southwestern Medical Center, Dallas, TX, 75390-8884, USA
Full list of author information is available at the end of the article
Davis et al. Clinical and Molecular Allergy 2011, 9:12
http://www.clinicalmolecularallergy.com/content/9/1/12 CMA
© 2011 Davis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.whether patients will respond to certain drug therapies,
to assess disease response to therapy, and to predict
unwanted drug side-effects [6,7]. While gene expression
changes have been used for a number of years to study
autoimmune diseases and cancer, less is known about the
changes seen with allergic diseases [8-10].
Allergy related genes have been identified through the
use of gene profiling, but little is known about gene
expression changes that occur with IT [11]. Liu et al. con-
ducted a study to evaluate gene expression changes in
patients undergoing IT. The goal of the study was to iden-
tify a unique gene profile in RIT patients compared to
healthy controls and those with autoimmune diseases. The
study followed 4 patients on RIT using a limited cDNA
microarray of 4100 genes. After 4 months on IT, the
authors identified under-expressed genes encoding apop-
tosis-related proteins, and over-expressed transcripts
encoding proteins involved in stress response and signal
transduction [12]. Another more recent study evaluated
patients on venom IT and identified osteopontin as a
potential biomarker [13].
In this study, our primary outcome was to examine
immunologic changes in a group of patients undergoing
RIT to multiple inhalant allergens. In addition to genome-
wide transcriptional profiling, we assessed whether RIT
would have an effect on basophil FcεRI expression as this
has not been looked at previously. With anti-IgE therapy,
surface FcεRI expression is known to decrease in correla-
tion with diminished free IgE levels[14]. We hypothesized
that changes in gene expression would be evident early in
the course of RIT. In addition, we monitored immunologic
parameters, including the frequency of CD3
+CD4
+CD25
bright T-regulatory cells, allergen-specific IgE and
IgG4 and basophil FcεRI expression.
Methods
Patient Selection
Eligible patients for this pilot study were recruited from
our university hospital allergy clinic. These studies were
approved by the Institutional Review Board at UT
Southwestern Medical Center. The patient blood sam-
ples were collected after obtaining written informed
consent from the study subjects. For this study, we
enrolled 3 patients undergoing RIT to multiple aeroal-
lergens. In order to qualify, patients had to demonstrate
skin test positivity to one of 4 common major aeroaller-
gens: bermuda grass, ragweed, and Dermatophagoides
(D.) pteronyssinus,o rD. farinae house dust mites. Only
adult patients who had ≥ a 5 mm wheal on prick testing
to at least 1 of the study allergens were eligible. Exclu-
sion criteria included those patients who had previously
received IT, or were on chronic corticosteroids, were
pregnant, used b-blocker medications, or had uncon-
trolled asthma.
Patients underwent RIT per our standard protocol: a
series of injections over a three hour period to achieve a
1:10 dilution of allergen concentrate with subsequent
build-up to undiluted allergen concentrate over the next
several weeks [15]. Our standard RIT protocol is outlined
in Table 1. The Rhinitis Symptom Severity Assessment
instrument was obtained prior to initiation and after 4
months of RIT (Table 2). This rhinitis symptom severity
questionnaire is a visual analog scale that scores nasal
(e.g. sneezing, runny nose) and non-nasal (e.g. chronic
cough, eye symptoms) symptoms. Each symptom is
scored between a one (none to an occasional episode) to
seven (unbearably severe) [16]. Appropriate samples were
collected from patients for each of the assays at various
timepoints as shown in Table 3.
RNA Extraction and Microarray Expression Profiling
Peripheral blood mononuclear cells (PBMC) from RIT
patients were used for the various assays. Of note, no sig-
nificant differences were observed in routine laboratory
blood cell counts and leukocyte differential values for
individual samples collected at the different timepoints.
To ensure minimum in vitro impact on the activation
status of the cells, we employed a modified gradient
separation. PBMC were immediately isolated by a rapid
Ficoll-Hypaque centrifugation for 15 min at 800 × g.
Cells were washed in PBS and cell numbers were
counted. Total cellular RNA was extracted from 10 mil-
lion PBMC with Trizol (Invitrogen) and immediately
stored at -80°C until further purified using the Qiagen
RNeasy Mini Kit. RNA integrity and quantity was con-
firmed by bioanalyzer. All cRNA probes, oligonucleotide
microarray manipulations, and scanning of the arrays
were carried out by our genomics and microarray core
facility adhering to stringent quality control criteria and
data processing that are detailed at the core website
(http://microarray.swmed.edu/) which also includes
numerous prior publications. PBMC mRNA gene expres-
sion changes over time were determined by oligonucleo-
tide microarrays using the Illumina Human-6 BeadChip
Table 1 Rush Immunotherapy Protocol
Injection Number Time (Min) Concentration
(Volume:Volume)
Volume
(ml)
1 0 1:10,000 0.3
2 30 1:1,000 0.3
3 60 1:100 0.1
4 90 1:100 0.3
5 120 1:10 0.1
6 180 1:10 0.2
Following the first day of RIT, the patient receives a weekly injection of
concentrate extract as follows: 0.02, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5 ml. Injections of
0.5 ml are given once at 2 weeks, then once at 3 weeks, then at monthly
intervals.
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flag calls of present. We assessed the statistical signifi-
cance of differentially expressed genes by standard meth-
ods. The data was normalized for all probe sets to the
median of all samples and the data was filtered for differ-
ential expression using the GeneSpring 7.3.1 Analysis
Platform (Agilent Technologies). For observed gene
expression changes over time with RIT, we compared the
initial 2 timepoints (pre-RIT and 1 week after the first
RIT treatment) with the final 2 timepoints (7 week and at
16 week post initiation of RIT). The comparisons were
subjected to statistical analysis as detailed in the text.
Annotation and functional assignments were assessed
with Ingenuity Pathways Analysis (IPA) Software (Inge-
nuity, Inc.). For analysis purposes the IPA software
assigns gene names (based on each probe, indicated in
parentheses in the text) to all mRNAs and associated
molecules, however, in many cases the gene and protein
names are identical. Microarray data is available through
the NCBI GEO database (GSE29521).
Flow Cytometry Analyses
Basophils were identified as Lin-1
-, HLA-DR
- and CD123
+
using BD Pharmingen antibodies. The BD Lineage cocktail
( L i n - 1 )c o n t a i n sa n t i b o d i e st oC D 3 ,C D 1 4 ,C D 1 6 ,C D 1 9 ,
CD20 and CD56. Basophil high-affinity receptor (FcεRI)
expression was detected with an antibody to FcεRI-alpha
(antibody clone AER-37 obtained from eBioscience). T
regulatory cells (CD3
+CD4
+CD25
bright) were identified at
each timepoint (Table 3) using directly-labeled antibodies
(BD Pharmingen) and detected by flow cytometry (BD
FACSCalibur).
Allergen-Specific Antibody Determinations
RIT patient serum samples were immediately aliquoted
and stored at -80°C. Samples were shipped on dry ice to
the Johns Hopkins Dermatology, Allergy and Clinical
Immunology. Allergen specific IgE levels, reported as kU
[A]/L (kilounits of allergen-specific IgE per liter), were
obtained using an ImmunoCAP250 device (Phadia
Uppsala, Sweden). Allergen specific IgG4 levels, reported
as mg [A]/L (milligram allergen-specific IgG4 per liter),
were obtained using a UniCap100 device (Phadia Uppsala,
Sweden). These results were analyzed courtesy of Dr.
Robert Hamilton of the Johns Hopkins Dermatology,
Allergy and Clinical Immunology Reference Laboratory,
which is a CLIA-88 certified clinical laboratory. Statistical
analysis of the results was carried out using a nonpara-
metric paired t-test (GraphPad Prism 5).
Results
Patient Demographics and Symptoms
Patient demographics are shown in Table 2. All three
patients were sensitive to bermuda grass and ragweed, and
two of the three patients were also sensitive to the two
dust mite species. All three patients demonstrated
improvement in their symptoms with two of three patients
having a large improvement in their allergic symptomatol-
ogy. None of the three patients were asthmatic.
Allergen Specific IgG
Allergen specific IgE and IgG4 levels are shown in
Figure 1. We analyzed these antibody levels at three
timepoints: pre-RIT, at 16 weeks (4 months)mainte-
nance dose, and after a one year follow-up. As with
Table 2 Patient Demographics and Symptom Assessment
Skin Test Positivity* Avg. Nasal
SymptomScore**
Patient Age Race Bermuda Ragweed D. Pteryon D.Farinae Baseline 4 mos. Post-RIT
1 56 Caucasian
++ 4.0 1.7
2 32 Caucasian
++ + + 5.1 2.9
3 28 Indian
++ + + 4.0 3.7
* + = greater than or equal to 5 mm on skin prick testing.
** Rhinitis Symptom Severity Score, Range 1 (no symptoms) to 7 (unbearably severe symptoms).
Table 3 Timetable for Collection of RIT Assessment and Samples
Timepoints
Pre RIT 1 week 7 week 16 week 52 week
Rhinitis Symptom Severity Assessment X X
Oligonucleotide Microarray X X X X
Basophil FcεRI expression X X X X X
Treg population X X X X X
Allergen specific IgE/IgG4 X X X
Patient samples were collected for the analyses shown over the course of the 52 week study. Routine laboratory blood cell counts were carried out at each visit
and are not shown.
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specific IgE with a downward trend at 1 year [17]. All
patients had an increase in allergen specific IgG4 at 1
year following RIT compared to baseline (ranging from
a 1.2 to a 63.8 fold increase). Specifically, the com-
b i n e dp r e - R I TB e r m u d aI g G 4l e v e l sw e r e0 . 4 3±0 . 3 1
(mean mg [A]/L ± SD) compared to one year levels of
4.68 ± 1.08 (p < 0.05), the pre-RIT Ragweed IgG4
levels were 0.50 ± 0.43 versus one year levels of 5.55 ±
2.69 and the combined dust mite species allergens
IgG4 levels were 1.0 ± 0.24 versus one year levels of
2.25 ± 0.24 (p < 0.05). Thus, these studies demonstrate
that RIT was effective at enhancing allergen specific
IgG4 levels that could be detected in the serum.
Transcriptional Profiles with RIT
We carried out whole genome expression profiling on
patient PBMC. We compared the initial 2 timepoints,
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Figure 1 Allergen specific IgE and IgG4 from RIT patients evaluated over time. Serum from each of the RIT patients was collected at
various timepoints, pre-RIT, at the 16 week (4 month) visit before RIT was administered and at the 52 week (12 month) visit before treatment.
Allergen specific IgE levels (kU [A]/L) were assessed by the ImmunoCAP250 method. Allergen specific IgG4 levels (mg [A]/L) were assessed by
the UniCap100 method. Aeroallergens included Bermuda grass (green circle), Ragweed (brown square), D. pteronyssinus (red up-triangle) and D.
farinea (blue down-triangle).
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points, 7 weeks and at 16 weeks (or 4 months) post-RIT.
To minimize the inclusion of genes not related to RIT,
we subjected the dataset to analysis by a Welch t-test
combined with a Benjamini and Hochberg False Discov-
ery Rate (BH-FDR) multiple testing correction with a
FDR of 5% to control for transcripts that might appear by
chance. A number of transcripts (507) were differentially
expressed at ≥1.5 fold (p < 0.05, BH-FDR). We examined
the cellular localization and biological processes for the
molecules represented by these transcripts by IPA analy-
sis (Additional file 1, Table S1). This global analysis
revealed that the majority of the transcripts were for
cytoplasmic molecules (32%) followed by molecules loca-
lized to the nucleus (26%), the plasma membrane (12%),
and the extracellular space (4%). The localization of the
molecules represented by the remaining transcripts (26%)
were unmapped. Two notable molecules that directly
regulate B cell function include Bruton’s tyrosine kinase
(BTK) and B-cell CLL/lymphoma 6 (BCL-6). Overall, the
proteins from these transcripts fell into diverse functional
categories including: enzymes (80), transcriptional regu-
lators (53), transporters (35), kinases (28), phosphatases
(19), peptidases (14), transmembrane receptors (14),
cytokines/chemokines (7), translational regulators (4),
ion channels (3), G-protein coupled receptors (3) and
ligand-dependent nuclear receptors (1). The molecular
functions for the proteins produced by the remaining
transcripts have yet to be identified.
At a ≥2 fold differential expression, 44 transcripts (p <
0.05, BH-FDR) were detected. Of these, 28 were up-regu-
lated and 16 were down-regulated. These transcripts were
subjected to unsupervised hierarchical clustering to group
the samples on the basis of similarity and visualized as
dendrograms. A significant alteration in the transcriptional
profile was readily detected between the pre and 1 week
post RIT sample as compared to samples collected at or
after 7 weeks (Figure 2). Of note, the first RIT patient also
had a 20 week (5 month) PBMC sample which was pro-
cessed for microarray as shown in Figures 2 and 3 (patient
1, column 5), however, the data for this patient was
excluded from the remainder of the analysis and the 20
week microarray results are shown only on the dendro-
grams. A select list of transcripts demonstrating the signif-
icant changes post-RIT is shown in Figure 3. Of note
IL-1b, IL-8, and CD40L were significantly up-regulated by
this analysis. In addition, other molecules known to regu-
late both innate and adaptive immune responses including
the chemokine CXCL1 and the dual specificity phospha-
tase 1, DUSP1, were up-regulated during RIT.
Basophil FcεRI Expression after RIT
Basophil FcεRI expression before and during the first
year of RIT is depicted in Figure 4. Interestingly, patient
3 had a steady decline in basophil FcεRI expression over
the year following RIT. Patient 3 also had the highest
baseline expression of basophil FcεRI expression. In
contrast, no consistent trend in basophil FcεRI expres-
sion was observed in patients 1 and 2.
CD4
+ T-regulatory populations after RIT
In defining T-regulatory cells as CD3
+CD4
+CD25
bright
cells, all three patients had a reduction in the percentage
of T regulatory cells from baseline to 16 weeks. How-
ever, at one year follow-up, only one patient exhibited a
persistent reduction in the frequency of circulating T-
regulatory cells (data not shown).
Discussion
Our results indicate that gene expression changes can be
observed early in the course of immunotherapy in PBMC
obtained from patients on a rush protocol. In fact, we
were able to identify several gene transcripts that appeared
to change as early as 1 week following RIT. In order to be
able to draw conclusions from this pilot study, we grouped
our samples from two timepoints. We separately com-
pared early timepoints (baseline and 1-week post-RIT)
with later timepoints (7 and 16 weeks post-RIT) when
patients were near or on a maintenance dosage of IT.
When analyzing the early versus later timepoints, we iden-
tified transcripts for well known molecules involved in the
regulation of immune responses such as IL-8, IL-1b,
CD40L, CXCL1, BCL-6, BTK and COX2 (PTGS2 gene)
which were all up-regulated. Interestingly, IL-8 (CXCL8)
demonstrated the greatest fold change of all up-regulated
transcripts. The chemokine IL-8 is well known to play a
role in the rapid mobilization of hematopoietic progenitor
cells and to induce both systemic and local leukocyte
migration [18]. Moreover, IL-8, IL-1b, and CXCL1 are
produced by monocytes and activate target cells during
inflammatory responses [18]. Whereas IL-8 was strongly
induced, CXCL1 was modestly up-regulated by 1.5 fold
change. Although the receptors for IL-8 and CXCL1 were
also up-regulated, CXCR1 by 1.3 fold change and CXCR2
by 1.8 fold change, they did not achieve statistical signifi-
cance, however, these results suggest that this pathway
demonstrated heightened activity in peripheral PBMC at 7
weeks and 16 weeks post initiation of RIT.
BCL-6 and Cyclooxygenase 2 (COX 2) act to promote
leukocyte survival [19,20]. Importantly, B cell differentia-
tion into plasma cells is regulated by CD40 Ligand
(CD40L or CD154) expressed by activated T cells. BCL-6
affects both innate and adaptive responses as BCL-6 is a
transcriptional repressor in dendritic cells and more
recently BCL-6 has been demonstrated to be a master
regulator for T follicular helper cell development in addi-
tion to its well known crucial role in germinal B cell for-
mation [20]. Thus expression of these transcripts likely
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allergen-specific IgG4 secreting B cell populations. Inter-
estingly, both DUSP1 (dual specificity phosphatase 1) and
COX2 are known regulators of inflammatory responses
and both have been associated with autoimmunity.
Therefore these gene expression changes appear to
reflect the pro-inflammatory process that is occurring at
early timepoints during successful RIT [21-23].
A survey of OMIM suggests that there is little infor-
mation regarding the proteins of the most statistically
significant, down-regulated transcripts with known func-
tion observed early in the leukocyte response to RIT
and that there is no clear correlation with pro-inflam-
matory responses. Several molecules identified by these
transcripts have been reported to be involved in tran-
scriptional regulation including: Ribosomal Protein L9
Patient 1                      Patient 2                  Patient 3 
Figure 2 Heat maps of differentially expressed transcripts (≥2-fold change, p ≤ 0.05) after hierarchical clustering was performed to
visualize up and down-regulated transcripts. The dendrogram shown compares pre-RIT and 1 week timepoints (columns 1 and 2 for each
patient) versus 7 and 16 week timepoints (columns 3 and 4 for each patient). Included is a 20 week PBMC sample which was collected and
processed for microarray for the first RIT patient only (patient 1, column 5). Overall there were 28 up-regulated transcripts and 16 down-
regulated transcripts. In the dendrogram red indicates increased expression relative to the median of all samples, blue indicates decreased
expression relative to the median of all samples and yellow indicates the median of all samples.
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Figure 3 Select up-regulated and down-regulated transcripts. The dendrogram shown highlights the variable expression that was observed
at different timepoints for individual patients although collectively many transcripts were coordinately up or down-regulated over the course of
the treatment. As above, the heat map is comparing pre-RIT and 1 week timepoints (columns 1 and 2 for each patient) versus 7 and 16 week
timepoints (columns 3 and 4 for each patient). The 20 week PBMC sample for the first RIT patient (patient 1, column 5) is also shown. As in
Figure 2, red indicates increased expression relative to the median of all samples, blue indicates decreased expression relative to the median of
all samples and yellow indicates the median of all samples.
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2( EEF1B2), which is a major protein in eukaryotic cells
that conducts the enzymatic delivery of aminoacyl
tRNAs to the ribosome and Cisplatin Resistance-asso-
ciated Overexpressed Protein (CROP)w h i c hi sam o l e -
cule found in all cells and that is involved in RNA
splicing [24-26]. Other down-regulated transcripts iden-
tified molecules including: Pyruvate Kinase, M2 (PKM2)
which is a glycolytic enzyme involved in cellular meta-
bolism, Clathrin, Heavy Polypeptide (CLTC)w h i c hi sa
major component of coated vesicles and coated pits and
Cell Division Cycle 10 (CDC10 or SEPT7)w h i c hi sa
molecule that is part of a signaling pathway involved in
the regulation of the DNA damage response to the
cytoskeleton and Carbonic Anhydrase I (CA1)w h i c hi s
a zinc metalloenzyme which has been implicated in lym-
phocyte maturation. Further pathway analysis of an
expanded lists of transcripts down-regulated in response
to RIT might further our understanding of the mechan-
isms regulating the leukocyte response to therapy.
We interrogated the dataset for known allergy-related
genes whose regulation might contribute to a therapeutic
response. We found that transcripts related to both TH1
and TH2 responses were ≥1.5 fold up-regulated in leuko-
cytes during RIT. These included transcripts for cytokine
and chemokine receptors such as: IFNGR1 (CD119),
IFNGR2, IL13RA1, CCR3, IL2RB, the TH2 transcription
factor GATA3, the apoptosis-related receptor TRAIL
(TNFSF10) and Caspase 3, an apoptosis-related cysteine
protease in addition to cell surface molecules CD33, CD89,
and CD53. Other transcripts of interest up-regulated by
≥1.4 fold included: TNF, A20,T R A F 1 ,T R A F 5 ,ITGAM,
CD44, CD32 and CD107b which have been implicated
in autoimmune and other diseases. Interestingly, the
transitional B cell markers CD10 and BTK, were up-
regulated by ≥1.7 fold suggesting ongoing alterations in
peripheral B cell maturation. Finally, type I interferon-
induced transcripts for the molecules MX-1, IFIT2,a n d
IRF1 were up-regulated by ≥1.7 fold. Although these results
are intriguing, the significance of these transcripts require
confirmation with a larger sample size and further dissec-
tion of the immune response during RIT. Taken together,
these finding suggest that RIT induces a rapid and potent
pro-inflammatory TH1 response that results in enhanced
IgG4 production by B cells to specific allergens.
Previous studies utilizing oligonucleotide microarrays
to analyze patients with allergic rhinitis have focused pri-
marily on comparing patients with an allergic phenotype
to healthy controls. Heishi et al., analyzed PBMCs in ato-
pic dermatitis patients and found 4 transcripts, (IFN-g,
TRAIL, ISGF-3, and defensin-1), through screening
GeneChip and confirmatory PCR, that were significantly
different in atopic dermatitis patients compared to
healthy controls [27]. Benson et al. analyzed nasal muco-
s a lb i o p s i e so fa l l e r g i cr h i n i t i sp a t i e n t sa n du s e dc D N A
microarrays to focus on 32 transcripts thought to be rele-
vant to mucosal inflammatory responses (e.g., cytokines,
growth factors, eosinophil, and neutrophil granulae pro-
teins) [28]. In comparing the allergic patients to healthy
controls, the authors found only modest differences in
the gene expressions of the 32 genes. More recently,
Zhang et al. analyzed gene expression of chemokines and
their receptors in the nasal mucosa AR patients com-
pared to healthy controls [29]. These authors found upre-
gulation of a majority of chemokines and chemokine
receptors in AR patients.
The only study, to our knowledge, to analyze gene
expression profiles in patients undergoing RIT was
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Figure 4 Basophil FcεRI expression for RIT patients over time. Basophils were identified as Lineage-1
-, HLA-DR
- and CD123
+ (BD antibodies).
Basophil high-affinity receptor (FcεRI) expression was detected with an antibody to FcεRI-alpha (eBioscience) and detected by flow cytometry
(BD FACSCalibur). Data are expressed as the normalized mean fluorescence intensity (MFI) of the RIT patient sample relative to a control in the
same experiment for each of the timepoints indicated including pre-RIT, 1 week post initiation of RIT and before treatment was administered
(post-RIT), 7 weeks post-RIT, 16 weeks post-RIT (4 months) and 52 weeks (1 year) post-RIT. Results for individual patients are presented as blue,
black and green bars.
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Page 7 of 10conducted by Liu et al. [12]. In that study, peripheral
blood samples were obtained for analysis prior to RIT
and at approximately 4 months when patients were on
maintenance IT. Limitations in that study include that
the analysis was performed at only 2 timepoints as well
as the microarray dataset analyzed only 4100 genes.
TGF-b was the only transcript that the authors identi-
fied with greater than a two-fold difference between
before and after immunotherapy, but the difference did
not reach statistical significance. In comparing our gene
expression results with previous studies, our findings are
unique. One strength of our study includes the fact that
we performed gene expression profiles at several early
timepoints during the course of RIT. By doing so, we
found gene expression changes as early as 1 week after
the initiation of RIT.
We analyzed the allergen specific antibodies, specifi-
cally IgE and IgG4, over the course of one year as a sec-
ondary outcome. As expected, the allergen specific IgE
for each allergen peaked at the 16 week (4 month) inter-
val before trending down. A previous RIT study following
IgE and IgG4 levels sequentially for patients on birch IT
found the peak IgE at 2 months before seeing a steady
decline at several timepoints out to 1 year [30]. This
same study found the allergen specific IgG4 levels to
steadily increase over time up to 1 year of IT. In our
patients, the allergen specific IgG4 levels were at the
highest amounts at the 1 year timepoint only for patient
2. For patients 1 and 3, the allergen specific IgG4 levels
peaked at the 4 month timepoint. If we had continued to
follow the allergen specific IgE and IgG4 further over
time, we predict a continued steady decline in the IgE
levels with a rise in IgG4 levels.
While we did not expect major changes in basophil
FcεRI expression, surprisingly, patient 3 showed a steady
decline over time after RIT. Interestingly, patient 3 also
had the highest baseline FcεRI expression. Since total IgE
is not affected by IT, this suggests that perhaps other reg-
ulatory factors may be involved with FcεRI expression.
We confirmed the validity of our FcεRI assay by assessing
the known down-regulation of FcεRI expression after
omalizumab therapy (Additional file 2, Figure S1). We
analyzed peripheral blood samples from 2 asthmatic non-
IT patients on chronic monthly omalizumab therapy and
these samples exhibited a striking down-regulation in
basophil FcεRI expression as compared to controls. To
our knowledge, no studies have looked at FcεRI expres-
sion changes with IT. This may be important component
to analyze in larger IT studies.
CD4
+ T-regulatory frequencies tended to be higher in 2
of 3 patients at the last timepoint. We did not observe a
steady increase in the percent of T-regulatory cells that
has been described with conventional IT [31]. Longer fol-
l o w - u pm a yb er e q u i r e dt od e m o n s t r a t em o r er o b u s t
changes. In addition, intracellular staining for FoxP3 or
gating on cells with low CD127 expression may more
accurately discriminate the peripheral population of T-
regulatory cells [32]. Alternatively, recent studies suggest
that T-regulatory cells could be organ-specific and thus
assessing frequencies in the periphery might not be opti-
mal for a given response [33,34].
Our study had several limitations. First, because this
was a pilot study, our small patient population is a lim-
itation. However, by grouping the patient samples, we
were able to strengthen the microarray analysis findings.
In addition, we enrolled patients undergoing RIT to
multiple allergens. This heterogeneity in allergens may
have confounded some of our results but it is common-
place in our clinical practice, to see allergic patients
with multiple sensitivities. We wished to evaluate a
more real-world scenario in which patients are receiving
IT to multiple allergens. Another potential limitation is
that we used PBMCs for all our analyses. Using nasal
biopsy samples may have yielded more robust findings,
in that a nasal biopsy analysis is focused on the specific
site of allergic inflammation. This invasive procedure is
difficult to perform, especially for the current study
which analyzed the same patients sequentially during
the first few weeks of their RIT. Nonetheless, we were
able to see significant changes in gene expression over
the course of RIT by employing PBMC.
In conclusion, this study of allergic rhinitis patients
undergoing multi-aeroallergen RIT revealed significant
changes in gene expression early after RIT. These stu-
dies support a model whereby RIT induces a rapid and
potent T helper cell response which alters B cell anti-
body production resulting in IgG4 which has the poten-
tial to bring relief from allergic symptoms.
Additional material
Additional file 1: Table S1: PBMC display differentially expressed
genes during RIT. An excel (.xls) spreadsheet depicts the expressed
genes identified by Ingenuity Pathway Analysis that were derived from
the 507 transcripts (≥1.5 fold change) sorted by biological function and
including the p-value and a description of the molecule as well as the
cellular localization.
Additional file 2: Figure S1: Basophil FcεRI expression is modulated
by omalizumab. Basophil FcεRI expression (gated as Lineage-1
-, HLA-DR
+ and CD123
+) is displayed as histograms for two experiments (A and B).
Isotype control antibody binding is shown for two asthma patients
(tinted histogram with gray lines) with similar results for healthy donors
(not shown). Basophil FcεRI expression is shown for healthy donors (gray
line) as controls and asthma patients on omalizumab for at least 3
months (black line).
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